Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Terminated

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry

Outcome
Stopped early. Results posted; single-arm, no comparisonCommercial reasons (Business decision)
Phase
Phase 1 / Phase 2
Status
Terminated
Study type
Interventional
Start
31 May 2017
Ended
30 August 2017
Enrollment
2 participants
Sites
4
Primary outcomes
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Sponsor type
Industry
Results posted
25 November 2024
Last update
25 November 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 25 November 2024
Primary outcome
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0IMM-101 in Combination With Anti PDL1 in Melanoma: 1 of 2Values: ParticipantsTime frame: Due to the early termination of the study the outcome measure timeframe was until study termination, an average of 3 months.No analysis posted for this outcome (outcome 1)
Participants
IMM-101 in Combination With Anti PDL1 in Melanoma: 2 started, 0 completed
Serious adverse events
IMM-101 in Combination With Anti PDL1 in Melanoma: 0 of 2Participants with at least one serious adverse event, of those at risk, as posted
4 secondary outcomes, the first 3 shown
Number of Participants With Treatment-related Adverse Events When IMM-101 is Given in Com…
IMM-101 in Combination With Anti PDL1 i… 1/2 [Participants]
Response to Treatment
immune related Stable Disease [irSD]: IMM-101 in Combination With Anti PDL1 i… 1/2 [Participants] (first of 3 rows)
OS · Overall Survival (OS)
IMM-101 in Combination With Anti PDL1 i… 0/2 [Participants]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type. The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens.

Detailed description public domain (ClinicalTrials.gov)

The study will consist of three phases - Screening, Treatment and Maintenance. Patients who provide informed consent, will participate in a Screening period of up to 28 days to establish eligibility. Once eligibility is confirmed, patients will enter the Treatment Phase of the study. In the Treatment Phase all patients will receive IMM-101 for 28 weeks. At Week 32, if the Investigator considers it in the patients' best interest patients will progress to the Maintenance Phase of the study and will continue to be dosed every 4 weeks (or as close to this interval as permitted due to practical or logistical considerations). Patients will be followed up for assessment of safety, response to treatment, survival, and immunological markers for up to 4.5 years.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 [Due to the early termination of the study the outcome measure timeframe was until study termination, an average of 3 months.]. Count Of Participants, Participants. IMM-101 in Combination With Anti PDL1 in Melanoma (n=2): 1.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 [Week 28 through study completion (maximum 4.5 years)].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Treatment-related Adverse Events When IMM-101 is Given in Combination With a Checkpoint Blockade Inhibitor [From screening until study termination an average of 3 months.]. Count Of Participants, Participants. IMM-101 in Combination With Anti PDL1 in Melanoma (n=2): 1.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Response to Treatment [Per protocol the initial assessment was at Week 28 then through study completion (maximum 4.5 years). Due to early termination of the study, response to treatment was measured at Week 11 for both patients]. Count Of Participants, Participants. immune related Stable Disease [irSD]: IMM-101 in Combination With Anti PDL1 in Melanoma (n=2): 1. immune related Partial Response [irPR]: IMM-101 in Combination With Anti PDL1 in Melanoma (n=2): 1. immune related Complete Response [irCR]: IMM-101 in Combination With Anti PDL1 in Melanoma (n=2): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) [From date of randomization until date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.]. Count Of Participants, Participants. IMM-101 in Combination With Anti PDL1 in Melanoma (n=2): 0.